Tech Company Financing Transactions
Bluejay Therapeutics Funding Round
Bluejay Therapeutics, based in San Mateo, secured $182 million from Frazier Life Sciences, Arkin Bio-Ventures and HBM Healthcare Investments.
Transaction Overview
Company Name
Announced On
5/9/2024
Transaction Type
Venture Equity
Amount
$182,000,000
Round
Series C
Investors
Proceeds Purpose
The company intends to use the funds to accelerate the clinical development of BJT-778, as the treatment for chronic hepatitis D (HDV) and support the progression of additional promising candidates in Bluejay's robust pipeline for the treatment for chronic hepatitis B.
Company Information
Company Status
Private & Independent
Industry
Healthcare Services
Mailing Address
951 Mariners Island Boulevard 300
San Mateo, CA 94404
USA
San Mateo, CA 94404
USA
Phone
Undisclosed
Website
Email Address
Overview
Bluejay is on a mission to illuminate a path toward curative treatments for serious viral and liver diseases. At Bluejay, we are discovering life-changing medicines and cures for people with viral and liver diseases, starting with chronic hepatitis B (CHB) and chronic hepatitis D (CHD).
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Keting Chu
Chief Medical Officer
Nancy Shulman
Chief Scientific Officer
Hassan Javanbakht
Vice President
Jeff Zablocki
VP - Bus. Development
Christopher Holterhoff
VP - Bus. Development
Kevin Lin
Browse more venture capital transactions:
Prev: 5/9/2024: Arcium venture capital transaction
Next: 5/9/2024: Renegade Plastics venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on funding rounds that are announced publicly. All VC database entries reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs